About VDDI Pharmaceuticals
VDDI, headquartered in Brentwood, TN, is a pharmaceutical development company formed to in-license and develop therapeutics indications in the areas of infectious disease, cancer, and cardiovascular disease. VDDI targets products that can have narrow indications for life-threatening medical conditions and that have the potential for fast track approval. VDDI focuses on pharmaceutical products where general proof-of-principle has already been established in pre-clinical or human testing, and where the properties are novel and offer significant potential advantages to what is currently either already in the market or in development. VDDI acquires rights to compounds from both private and public partners, pursues fast track approval, develops compounds through Phase II of the required regulatory approval processes and then seeks to license these products to its partners for late stage development and marketing. For more information, visit www.virtualdrugdevelopment.com.

About Paradigm Genetics, Inc.
Paradigm Genetics, Inc. (Nasdaq: PDGM), headquartered in Research Triangle Park, NC, is an integrated life sciences company developing new technologies to discover products for the advancement of human health, agriculture and nutrition. In human health, Paradigm uses its proprietary MetaVantageTM technology to transform drug discovery and development, significantly enhancing the ability to understand and commercialize drug targets, lead compounds, and predictive medicine. MetaVantageTM elucidates the metabolic profile of a cell, tissue, or fluid, and integrates this information with data from other genomics analyses using Paradigm's proprietary comprehensive informatics system. By globally interrogating biochemistry, MetaVantageTM extends beyond traditional genomic technologies to reveal the next level of cellular information. For more information, visit www.paradigmgenetics.com.

This press release contains forward-looking statements, including statements regarding Paradigm's ability to develop novel technologies to speed the discovery of products for the advancement of human health, agriculture and nutrition, the value of its metabolomics technology for the drug discovery and development process and its ability to integrate biochemical profiles with other genomics analyses. Such forward-looking statements are based on management's current expectations and are subject to a number of risks, factors and uncertainties that may cause actual results, events and performance to differ materially from those referred to in the forward-looking statements. These risks include, but are not limited to, Paradigm's early stage of development, history of net losses, technological and product development uncertainties, reliance on research collaborations, uncertainty of additional funding and ability to protect its patents and proprietary rights. These and other risks are identified in Paradigm's report on 10-Q for the quarter ended September 30, 2001, filed with the Securities and Exchange Commission.

MetaVantage™ is a U.S. trademark of Paradigm Genetics, Inc.

-- end --